Vilon
A synthetic dipeptide (Lys-Glu) from the Khavinson bioregulator family, studied for thymic and immune system bioregulation and geroprotective effects.
Also referenced as: KE, Lys-Glu
Also appears in: Longevity
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary lane: Immune. Also surfaces under Longevity for browsing and discovery.
KE, Lys-Glu
FDA label signal · 748 trials · 4709 PubMed results
Current evidence for Vilon is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
Vilon has no clinical trials that name it and 4709 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Vilon?
Vilon is a synthetic dipeptide with the sequence Lys-Glu (KE), the shortest peptide in the Khavinson bioregulator family. It is classified as a thymus and immune system bioregulator. Despite being only two amino acids, the Khavinson group proposes it has tissue-specific biological activity.
How it works
- Immune modulation — Vilon is theorized to support thymic function and T-lymphocyte maturation through tissue-specific gene regulation (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011)
- Geroprotective effects — in the Khavinson framework, KE dipeptide is proposed to interact with DNA in thymocytes and modulate gene expression relevant to immune senescence (Khavinson, Gerontology, 2005)
- Thymic involution — the thymus progressively atrophies with age; Vilon is theorized to counteract this process, though direct evidence is limited to cell culture and animal studies from the Khavinson group
Research status
- Khavinson (2005) reviewed peptide bioregulators including the KE dipeptide (Gerontology, 51(2):70–75)
- Khavinson et al. (2002) reported effects of short peptides on thymocyte chromatin in aging (Bulletin of Experimental Biology and Medicine, 133(5):473–475)
- No independent Western replication studies or clinical trials
Key considerations
- The smallest Khavinson bioregulator — only 2 amino acids, raising questions about specificity and mechanism
- Part of the same bioregulator family as Thymalin (the full thymic extract) and Thymagen
- Available from research vendors as lyophilized powder or capsules